|
|
Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 10 (May 15), 1999:
pp. 3267-3275
Influence of Intestinal Bacterial Decontamination Using
Metronidazole and Ciprofloxacin or Ciprofloxacin Alone on the
Development of Acute Graft-Versus-Host Disease After Marrow
Transplantation in Patients With Hematologic Malignancies: Final
Results and Long-Term Follow-Up of an Open-Label Prospective
Randomized Trial
Dietrich W. Beelen,
Ahmet Elmaagacli,
Karl-Dieter Müller,
Herbert Hirche, and
Ulrich W. Schaefer
From the Departments of Bone Marrow Transplantation, Medical
Microbiology, and Medical Informatics, Biometry and Epidemiology,
University Hospital of Essen, Essen, Germany.
In a single-center open-label prospective study, a total of 134 marrow transplant recipients with hematologic malignancies were
randomly assigned to a bacterial decontamination medication using
metronidazole and ciprofloxacin (n = 68) or ciprofloxacin alone (n
= 66) during 5 weeks posttransplant. The development of grades II to
IV acute graft-versus-host disease (GVHD) was defined as the primary
study endpoint. According to the intention-to-treat, 17 patients (25%)
randomized to the combined decontamination medication and 33 patients
(50%) randomized to ciprofloxacin alone developed grades II to IV GVHD
(P < .002). The higher frequency of grades II to IV acute
GVHD in patients randomized to ciprofloxacin alone resulted from a more
than twofold increased number of patients developing liver or
intestinal involvement with acute GVHD compared with patients
randomized to the combined decontamination medication (P < .003). The influence of the study medication on grades II to IV acute
GVHD was significant only in recipients of transplants from
genotypically HLA-identical sibling donors (n = 80), whereas in
recipients of transplants from donors other than HLA-identical siblings
(n = 54), grades II to IV acute GVHD frequencies between the study
arms were not significantly different. The combined decontamination was
associated with a significant reduction of culture growth of intestinal
anaerobic bacteria during 5 weeks posttransplant (P < .00001). In addition, the number of cultures with growth of anaerobic
bacteria (P < .005) as well as the median concentrations of
anaerobic bacteria in the posttransplant period (P < .0001)
were higher in patients contracting grades II to IV acute GVHD. Neither
chronic GVHD nor overall survival was significantly different between
the two study arms. In patients with HLA-identical sibling donors who
were treated in early disease stages, the 5-year survival estimate was
slightly, but not significant, higher after the combined
decontamination medication (60% ± 11%) compared with ciprofloxacin
alone (46% ± 9%). In conclusion, the present study provides
evidence that antimicrobial chemotherapy targeted to intestinal
anaerobic bacteria in marrow transplant recipients significantly
reduces the severity of acute GVHD and supports the theory that the
intestinal anaerobic bacterial microflora plays a role in the
pathogenesis of acute GVHD after human marrow transplantation.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Calcaterra, L. Sfondrini, A. Rossini, M. Sommariva, C. Rumio, S. Menard, and A. Balsari
Critical Role of TLR9 in Acute Graft-versus-Host Disease
J. Immunol.,
November 1, 2008;
181(9):
6132 - 6139.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Hauser, O. Zach, O. Krieger, H. Kasparu, J. Koenig, M. Girschikofsky, R. Oberbauer, and D. Lutz
A single nucleotide polymorphism at chromosome 2q21.3 (LCT -13910C>T) associates with clinical outcome after allogeneic hematopoietic stem cell transplantation
Blood,
September 1, 2008;
112(5):
2156 - 2159.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M M Heimesaat, A Fischer, H-K Jahn, J Niebergall, M Freudenberg, M Blaut, O Liesenfeld, R R Schumann, U B Gobel, and S Bereswill
Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli
Gut,
July 1, 2007;
56(7):
941 - 948.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Heimesaat, S. Bereswill, A. Fischer, D. Fuchs, D. Struck, J. Niebergall, H.-K. Jahn, I. R. Dunay, A. Moter, D. M. Gescher, et al.
Gram-Negative Bacteria Aggravate Murine Small Intestinal Th1-Type Immunopathology following Oral Infection with Toxoplasma gondii
J. Immunol.,
December 15, 2006;
177(12):
8785 - 8795.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. E. Beck, J. A. Blansfield, K. Q. Tran, A. L. Feldman, M. S. Hughes, R. E. Royal, U. S. Kammula, S. L. Topalian, R. M. Sherry, D. Kleiner, et al.
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4
J. Clin. Oncol.,
May 20, 2006;
24(15):
2283 - 2289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Holler, G. Rogler, J. Brenmoehl, J. Hahn, H. Herfarth, H. Greinix, A. M. Dickinson, G. Socie, D. Wolff, G. Fischer, et al.
Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination
Blood,
May 15, 2006;
107(10):
4189 - 4193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. K. Takahashi, H. Iwagaki, D. Xue, G. Katsuno, S. Sugita, K. Mizuno, S. Mori, S. Saito, T. Yoshino, N. Tanaka, et al.
Effect of Ciprofloxacin-Induced Prostaglandin E2 on Interleukin-18-Treated Monocytes
Antimicrob. Agents Chemother.,
August 1, 2005;
49(8):
3228 - 3233.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Elmaagacli, M. Koldehoff, N. K. Steckel, H. Hindahl, R. Trenschel, H. Ottinger, and D. W. Beelen
Mutations Innate Immune System NOD/CARD15 Gene and Toll-Like-Receptor-4 Gene Are Associated with Increased Risk for Severe Acute Gvhd in Patients Who Underwent Allogeneic Transplantation.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
425 - 425.
[Abstract]
|
 |
|

|
 |

|
 |
 
T. Iwasaki
Recent Advances in the Treatment of Graft-Versus-Host Disease
Clin. Med. Res.,
November 1, 2004;
2(4):
243 - 252.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Heslop
Graft-versus-yogurt
Blood,
June 1, 2004;
103(11):
4000 - 4001.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gerbitz, M. Schultz, A. Wilke, H.-J. Linde, J. Scholmerich, R. Andreesen, and E. Holler
Probiotic effects on experimental graft-versus-host disease: let them eat yogurt
Blood,
June 1, 2004;
103(11):
4365 - 4367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie
Infections in Patients with Hematological Cancer: Recent Developments
Hematology,
January 1, 2003;
2003(1):
438 - 472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Cooke, K. Olkiewicz, N. Erickson, and J. L.M. Ferrara
The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease
Innate Immunity,
December 1, 2002;
8(6):
441 - 448.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Marr, K. Seidel, M. A. Slavin, R. A. Bowden, H. G. Schoch, M. E. D. Flowers, L. Corey, and M. Boeckh
Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial
Blood,
September 15, 2000;
96(6):
2055 - 2061.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. R. Hill and J. L. M. Ferrara
The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation
Blood,
May 1, 2000;
95(9):
2754 - 2759.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|